Jason Blum and James Wan have put a single name on their combined horror operation: Blumhouse Atomic. Announced Tuesday, the rebrand covers the company created by the 2024 merger of Blumhouse and Atomic Monster, while both banners keep operating as distinct production labels.
The name change matters less than the arithmetic behind it.
Cheap horror, outsized returns
Since the merger, the combined company says its horror slate has generated more than $2.5 billion in worldwide box office against combined production budgets of less than $330 million. That includes more than $1 billion in worldwide box office in each of 2025 and 2026.
The return multiple is the story: roughly seven and a half dollars of worldwide gross for every dollar of production budget since the merger. That is precisely the kind of math the theatrical business has struggled to find in big-budget swings, and it explains why the horror model keeps attracting capital and platform partners.
This year is the sharper proof point: nearly $1.3 billion in global ticket sales on less than $70 million in production spend. Breakouts such as Curry Barker’s “Obsession” and Kane Parsons’ “Backrooms” show the model working on original stories, not just legacy franchises.
For streaming and TV buyers, this is not just a box-office headline. It means the company can keep feeding a pipeline of low-cost, high-awareness titles and franchises into licensing and commissioning conversations without the risk profile of a tentpole misfire.
“We have the output of a studio with the creative freedom and financial discipline of an independent company,” Jason Blum said.
Franchise rights and the next voices
Blum pointed to the “Saw” rights deal as a test case. “Bringing ‘Saw’ back to James, with a new chapter on the way, is a perfect example of what we can do together,” he said.
The company is pairing that discipline with IP expansion. Blumhouse acquired prospective rights to “Saw” in 2025, reuniting Wan with the franchise he co-created with Leigh Whannell. Lionsgate keeps its existing ownership and distribution rights, while Content Partners and Mark Burg hold interests in the existing library. New “Paranormal Activity” and “Blair Witch” installments are also in the works.
To broaden its pipeline, Blumhouse Atomic hired Sam Zimmerman as Senior Vice President, Development and Acquisitions earlier this year to oversee genre features including projects with budgets under $5 million. A late-2025 first-look deal with Divide/Conquer adds high-concept, cost-efficient genre films.
Wan framed the strategy around access. “The future of horror comes from new voices,” he said, adding that giving emerging filmmakers the chance he once had is personal.
The 2027 slate and beyond the theater
The announced 2027 slate leans on both originals and returning franchises:
- “River,” “The Revenge of La Llorona,” “The Exorcist: Martyrs” and “Anything But Ghosts”
- “Paranormal Activity,” “Molepeople,” “Blair Witch,” “Sleepover” and “Seasons”
Blumhouse Atomic is also extending its stories into television, gaming and live entertainment: “The Rainmaker” for USA Network, “Scarpetta” for Prime Video, “Worst Ever” for Netflix, the game “Grave Seasons,” “Paranormal Activity” on Broadway, and collaborations with Universal Halloween Horror Nights.
The expansion mirrors how modern horror IP travels: a film becomes a series, a game, a theme-park activation and e-commerce. Each window reaches a slightly different audience and amortizes the underlying franchise investment further.
For media planners and platform buyers, the signal is straightforward: horror remains one of the entertainment economy’s most reliable return-on-spend engines, and the IP is increasingly being sold across the full attention stack rather than only theaters.
Source: TheWrap
